StimCell Enegetics

StimCell Enegetics FCF Margin

The Free Cash Flow Margin of StimCell Enegetics (STME) as of Oct 21, 2026 is -9,855.50 %. In the previous year, Free Cash Flow Margin was -7,429.37 % — a change of 32.66% (lower).

FCF Margin

-9,855.50 %

YoY

32.66%

Last updated:

Free Cash Flow Margin of StimCell Enegetics is 2023 -9,855.50 % . Free Cash Flow Margin of StimCell Enegetics was 2022 -7,429.37 % . It decreases by 32.66% lower compared to the previous year.

The StimCell Enegetics FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2015
-942.67 USD
Jan 1, 2016
-1,751.68 USD
Jan 1, 2017
-13,895.39 USD
Jan 1, 2019
-322.94 USD
Jan 1, 2020
-968.76 USD
Jan 1, 2021
-9,266.38 USD
Jan 1, 2022
-7,429.37 USD
Jan 1, 2023
-9,855.50 USD
The StimCell Enegetics FCF Margin history
YEARFCF MarginYoY
-9,855.50 %+32.66%
-7,429.37 %-19.82%
-9,266.38 %+856.52%
-968.76 %+199.98%
-322.94 %-97.68%
-13,895.39 %+693.26%
-1,751.68 %+85.82%
-942.67 %+969.28%
-88.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StimCell Enegetics Stock analysis

What does StimCell Enegetics do? Cell MedX Corp. makes money through its subsidiary Avyonce Cosmedics Inc., which resells spa technology and equipment to the beauty and wellness industry. Avyonce also markets eBalance Technology, used for micro current treatments targeting diabetes and related ailments, and conducts observational studies with this technology. The company provides continuing education for estheticians and healthcare professionals in medical aesthetics. Avyonce Cosmedics Inc. serves the beauty and wellness industry, focusing on professionals who use spa technology and equipment. The firm develops a family of devices based on eBalance Technology, which is applied in treatments for diabetes and related conditions. This technology is central to Avyonce's product offerings and educational services. Cell MedX Corp. operates as a development stage company with no full-time employees, relying on its subsidiary Avyonce to drive revenue. The company's business model centers on the commercialization of eBalance Technology through product sales, educational programs, and observational studies in the medical aesthetics sector. StimCell Enegetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StimCell Enegetics stock

Free Cash Flow Margin of StimCell Enegetics is -9,855.50 % in 2023.

Free Cash Flow Margin of StimCell Enegetics changed from -7,429.37 % to -9,855.50 %, representing a 32.66% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin StimCell Enegetics since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's StimCell Enegetics with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — StimCell Enegetics

All Key Metrics — StimCell Enegetics